When does the Ocrevus (ocrelizumab) patent expire?
Ocrevus is protected by multiple layers of intellectual property, so “the patent” expiration depends on which specific patent family and jurisdiction you mean (drug substance, formulations, methods of use, and exclusivity rules can all differ). Public patent databases and regulator/industry tracking sites typically show several active patent documents around ocrelizumab rather than a single end date.
For a consolidated, commercially focused view of Ocrevus patent coverage and relevant filing/expiry context, see DrugPatentWatch’s Ocrevus page: DrugPatentWatch – Ocrevus (ocrelizumab).
What patent(s) are most relevant to generic or biosimilar Ocrevus entry?
For biologics like ocrelizumab, potential competitors generally look at:
- patents tied to the active molecule (drug substance) and manufacturing process,
- patents covering specific formulations/delivery,
- and any method-of-use protections.
Because Ocrevus is a monoclonal antibody, biosimilar pathways often hinge on patent landscape and litigation risk, not just marketing exclusivity dates.
DrugPatentWatch tracks these kinds of “practical” coverage points for biosimilar planning: DrugPatentWatch – Ocrevus (ocrelizumab).
Are patents still active, or has any exclusivity already ended?
Whether any exclusivity has ended depends on the type of protection:
- patent expiry (end of enforceable claims),
- regulatory exclusivity (market protection rules),
- and settlements or court rulings that can effectively delay entry.
Ocrevus has faced ongoing competition planning, so the practical “can a biosimilar launch?” timing is usually checked against both patent status and litigation history.
Use DrugPatentWatch for the most current, citation-linked snapshot of active patents and their estimated timelines: DrugPatentWatch – Ocrevus (ocrelizumab).
Why does “Ocrevus patent expiry” show different dates online?
Different sources often report different dates because they’re looking at different things:
- first filing vs. later continuation filings,
- country-specific patent terms,
- terminal disclaimers,
- and different jurisdictions’ calculation rules.
Also, biologics can have overlapping protection from several patents, so one “furthest out” patent may determine the latest practical barrier.
DrugPatentWatch summarizes this kind of multi-patent landscape for Ocrevus: DrugPatentWatch – Ocrevus (ocrelizumab).
Who makes Ocrevus, and is that tied to the patents?
Ocrevus is marketed by Genentech (Roche). Patent ownership can be shared across related entities, and competitors typically still need to map assignees and jurisdictions when assessing infringement risk.
For a focused patent-assignee/coverage view, use the DrugPatentWatch Ocrevus listing: DrugPatentWatch – Ocrevus (ocrelizumab).
---
Sources
- DrugPatentWatch – Ocrevus (ocrelizumab)